Within KRAS-mutant lung cancer, three subtypes are defined by co-mutation of TP53, STK11, or other genes and these subtypes have critical implications for prognosis and treatment options (Skoulidis et al. 2015, 2018; Skoulidis and Heymach 2019). The gene discussed is KRAS; the disease is lung carcinoma.